Hence we asked whether the combination of 17-AAG, responsible for induction of Tyrp1, and adoptive transfer of cytotoxic CD4+ T cells specific for Tyrp1 can enhance the anti-tumor immune response by delaying recurrence of B16 melanomas. The gene discussed is CD4; the disease is neoplasm.